Centers for Disease Control and Prevention

Global Influenza Vaccines Research Analysis Report 2023: A Potential $10.9 Billion market by 2030 - Expanding Manufacturing Capabilities and Focus on Launching New Vaccines will Propel Expansion

Retrieved on: 
Tuesday, August 29, 2023
Vaccine, GSK plc, Vaccination, Influenza, Sinovac Biotech, Pfizer, AstraZeneca, CIC, Centers for Disease Control and Prevention, Government, CDC, Trial of the century, Death, Incidence, Pandemic, Investment, Risk, Sanofi, Growth, Ageing, WHO, Immunization, Messenger, World Health Organization, Pharmaceutical industry, EU, CSL Limited

The increasing R&D investments by leading market players, such as Sanofi, CSL Limited, and GlaxoSmithKline, for expanding manufacturing capabilities and focus on launching new vaccines will propel the market for influenza vaccines over the forecast period.

Key Points: 
  • The increasing R&D investments by leading market players, such as Sanofi, CSL Limited, and GlaxoSmithKline, for expanding manufacturing capabilities and focus on launching new vaccines will propel the market for influenza vaccines over the forecast period.
  • Geographically, North America is the largest market for influenza vaccines capturing over 50% market share in 2022.
  • AstraZeneca influenza vaccines sales declined by 31% in 2022, owing to late start to the influenza season in Europe.
  • In 2021, Seqirus influenza vaccines sales increased by 37% over the prior year, driven by strong growth in seasonal influenza vaccines.

Strive Health Announces Multi-Year National Collaboration with Oak Street Health

Retrieved on: 
Wednesday, August 23, 2023
Practice Management, Managed Care, Surgery, General Health, Health, Medical Devices, Health Insurance, Other Health, Hospital, Patient satisfaction, Nephrology, CVS, Quality of life, Multimedia, Bangladesh Technical Education Board, Centers for Disease Control and Prevention, Dialysis, Kidney disease, Organization, Medicare, Social, Striving, NEA, Patient, Practitioner, Risk, Oak Street Health, Entrepreneurship, System, CVS Health, ESKD, CKD, Disease, Pharmaceutical industry, Nursing

Strive Health , a national leader in value-based kidney care, and Oak Street Health , a network of value-based primary care centers for adults on Medicare, have launched a multi-year national collaboration focused on people with stage 4 chronic kidney disease (CKD) through end-stage kidney disease (ESKD) across the 21 states in which Oak Street Health currently operates.

Key Points: 
  • Strive Health , a national leader in value-based kidney care, and Oak Street Health , a network of value-based primary care centers for adults on Medicare, have launched a multi-year national collaboration focused on people with stage 4 chronic kidney disease (CKD) through end-stage kidney disease (ESKD) across the 21 states in which Oak Street Health currently operates.
  • View the full release here: https://www.businesswire.com/news/home/20230823283573/en/
    Through this collaboration, Strive Health will bring value-based kidney care to Oak Street Health centers across the country.
  • (Photo: Business Wire)
    “We focus on delivering compassionate kidney care and Oak Street Health offers the best clinical care model for older adults, so bringing the organizations together in collaboration is a natural fit,” said Will Stokes, Co-Founder and Chief Strategy Officer at Strive.
  • “Strive is the right fit as we look to provide this additional comprehensive care to our late-stage CKD and ESKD patients that we serve at our centers,” said Drew Crenshaw, Chief Population Health Officer at Oak Street Health.

Northwell brings transplant, primary care services to New Jersey

Retrieved on: 
Tuesday, August 22, 2023
General Health, Hospitals, Health, Practice Management, Managed Care, CMS, Chronic liver disease, Hepatology, Liver disease, Centers for Disease Control and Prevention, Multimedia, Northwell Health, U.S. News & World Report, Teaching hospital, North Shore University Hospital, Suite, MD, Patient, Death, News, Hospital, Dentistry

Northwell Health Physician Partners (NHPP) has begun offering primary care, specialty services and a focus on the full array of liver diseases in Edgewater, N.J.

Key Points: 
  • Northwell Health Physician Partners (NHPP) has begun offering primary care, specialty services and a focus on the full array of liver diseases in Edgewater, N.J.
  • View the full release here: https://www.businesswire.com/news/home/20230822758463/en/
    Dr. Nabil Dagher, vice president and director of the Northwell Transplant Institute, meets with a patient.
  • (Photo: Business Wire)
    The services include hepatology and liver transplant specialists through the Northwell Transplant Institute in Manhasset, N.Y.
  • “We’re excited to bring transplant services to northern New Jersey,” said Nabil Dagher, MD , vice president and director of the Northwell Transplant Institute.

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

Retrieved on: 
Tuesday, August 22, 2023
Patent, Travel, Maryland Department of Commerce, Marketing, Centers for Disease Control and Prevention, Immunity, Infection, CDC, Plasmodium falciparum, Tafenoquine, Physician, Maryland Department of Health, Ageing, Disease, Malaria, Vaccine, Pharmaceutical industry, Plasmodium

Tafenoquine is the active molecule in ARAKODA®, the Company’s FDA-approved drug for malaria prevention in individuals aged 18 years and older for up to six months of continuous dosing.

Key Points: 
  • Tafenoquine is the active molecule in ARAKODA®, the Company’s FDA-approved drug for malaria prevention in individuals aged 18 years and older for up to six months of continuous dosing.
  • Travelers from and residents of the United States are usually malaria naïve, that is, they have not previously contracted malaria and thus lack immunity to the disease.
  • 60P initially received a U.S. patent in 2019 for tafenoquine for the prevention of P. falciparum malaria in naïve individuals aged 18 years of age or older.
  • The current patent award is a continuation of the application for that original patent.

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Retrieved on: 
Tuesday, August 22, 2023
EUA, SARS-CoV-2, Centers for Disease Control and Prevention, Allergy, Medicine, Completeness, Arthralgia, Vaccination, Hospital, COVID-19, Chills, Section, Fever, Immunodeficiency, Coronavirus, Myocarditis, Pericarditis, COVID, History, Person, Immunocompetence, Messenger, CDC, Emergency Use Authorization, Myalgia, Research and development, Development, Hypoesthesia, Anaphylaxis, XBB, VAERS, NVAX, FDA, Headache, Death, Paresthesia, MIS, FD, Pharmaceutical industry, Vaccine, Novavax COVID-19 vaccine, Adjuvant, Novavax, Research

Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.

Key Points: 
  • Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.
  • Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted.
  • Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.
  • The reports should include the words "Novavax COVID-19 Vaccine, Adjuvanted EUA" in the description section of the report.

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Retrieved on: 
Tuesday, August 22, 2023
EUA, SARS-CoV-2, Centers for Disease Control and Prevention, Allergy, Medicine, Completeness, Arthralgia, Vaccination, Hospital, COVID-19, Chills, Section, Fever, Immunodeficiency, Coronavirus, Myocarditis, Pericarditis, COVID, History, Person, Immunocompetence, Messenger, CDC, Emergency Use Authorization, Myalgia, Research and development, Development, Hypoesthesia, Anaphylaxis, XBB, VAERS, NVAX, FDA, Headache, Death, Paresthesia, MIS, FD, Pharmaceutical industry, Vaccine, Novavax COVID-19 vaccine, Adjuvant, Novavax, Research

Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.

Key Points: 
  • Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.
  • Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted.
  • Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.
  • The reports should include the words "Novavax COVID-19 Vaccine, Adjuvanted EUA" in the description section of the report.

Lundquist Principal Investigator Dr. Michael Yeaman Awarded $11.5 Million NIAID/HHS Grant for Innovative Research To Understand and Solve Persistent Bloodstream Infections

Retrieved on: 
Tuesday, August 15, 2023
Vaccine, Infection, DNA, Duke University Hospital, Centers for Disease Control and Prevention, Genetics, TLI, Epigenomics, Public, National Institute of Allergy and Infectious Diseases, MRSA, Immunity, Biomedical Research, Hope, Research, Antimalarial medication, Staphylococcus, Doctor of Philosophy, Bangladesh Technical Education Board, CDC, Harbor–UCLA Medical Center, Molecular medicine, Principal investigator, Division, Risk, Immune system, Nightfall and Other Stories, Biological engineering, NIAID, Principal, UCLA, United States Department of Health and Human Services, NIH, Bloodstream infections, Pharmaceutical industry, Health, Medicine, U19

In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.

Key Points: 
  • In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.
  • The focus of this U19 is on infections caused by the bacterium Staphylococcus, including methicillin-resistant S. aureus (MRSA) and the invasive fungus, Candida.
  • Dr. Yeaman and team made previous discoveries that laid essential groundwork for this project to find new ways to prevent and treat persistent bloodstream infections.
  • “We will use state-of-the-art technologies in synergistic research to understand human-pathogen interactions driving persistence,” said Dr. Yeaman.

Cloudious9 Releases the TrimCraft9, the Ultimate Tool for Precision Trimming and Efficiency

Retrieved on: 
Thursday, August 17, 2023
Lifestyle, Retail, Consumer, Millennials, Specialty, Generation Z, Generation X, Trigger, Centers for Disease Control and Prevention, Hardness, Horticulture, DSM-IV codes, Multimedia, CDC, Risk, Occupational safety and health, NIOSH, Safety, Carpal tunnel syndrome, Poultry farming

Developed by seasoned industry trimmers, the TrimCraft9 addresses and eliminates the most notorious pain points of trimming, delivering unparalleled efficiency and comfort for professional trimmers and home hobbyists.

Key Points: 
  • Developed by seasoned industry trimmers, the TrimCraft9 addresses and eliminates the most notorious pain points of trimming, delivering unparalleled efficiency and comfort for professional trimmers and home hobbyists.
  • Adjustable Blade Angles: Easily switch between Precision and Wide Trim Angle modes for tailored trimming, offering exceptional adaptability.
  • Dynamic Trimming Options: Single or continuous blade action to suit different applications, offering uninterrupted trimming power.
  • Residue Prevention Blade Coating: Stainless steel blades with food-safe coating for easy cleaning, efficiency, and extended durability.

Walgreens Announces New Vaccination and Testing Offerings Ahead of Fall Respiratory Virus Season

Retrieved on: 
Wednesday, August 16, 2023
Retail, Health, Infectious Diseases, Convenience Store, General Health, Pharmaceutical, Vaccine, Vaccination, Pharmacy, COVID-19, Multimedia, Centers for Disease Control and Prevention, CDC, Pharmacist, Friction, RSV, MD, Patient, Personal care, Pharmaceutical industry, Walgreens

Walgreens is offering in-store vouchers and off-site vaccination clinics through its employer vaccination program, and is rolling out a low-cost, 2 results in 1 test for flu and COVID-19 this fall respiratory virus season.

Key Points: 
  • Walgreens is offering in-store vouchers and off-site vaccination clinics through its employer vaccination program, and is rolling out a low-cost, 2 results in 1 test for flu and COVID-19 this fall respiratory virus season.
  • View the full release here: https://www.businesswire.com/news/home/20230816575526/en/
    Walgreens is offering in-store vouchers and off-site vaccination clinics through its employer vaccination program, and is rolling out a low-cost, 2 results in 1 test for flu and COVID-19 this fall respiratory virus season.
  • Walgreens is offering flu and respiratory syncytial virus (RSV) vaccination appointments nationwide and will provide the new Centers for Disease Control and Prevention (CDC) recommended COVID-19 vaccine once available later this fall.
  • To make a vaccination or testing appointment, individuals can visit Walgreens.com/ScheduleVaccine or Walgreens.com/Testing, download the Walgreens app or call 1-800-WALGREENS.

Pelago Achieves Healthcare Cost Savings of $9,367 (3x ROI) in First Ever Substance Use Management Medical Claims Analysis

Retrieved on: 
Thursday, August 17, 2023
Presenteeism, Sherwani, Pancreatitis, Medicine, Obesity, Depression, Suds, Liver disease, University Challenge 2013–14, Anxiety, Parent, Overalls, Absenteeism, Cardiovascular disease, Risk management, Research, Centers for Disease Control and Prevention, Tobacco, Wilcoxon, Substance, CDC, Randomized controlled trial, SUD, Adolescence, Ageing, ROI, Smoking, Mental health, Pharmaceutical industry, Pelago

NEW YORK, Aug. 17, 2023 /PRNewswire/ -- Pelago (formerly Quit Genius), the leading digital clinic partner to U.S. businesses and health plans for substance use management, today announced results of its substance use disorder (SUD) claims analysis. The analysis demonstrated that Pelago reduced medical claims on an annual basis by $9,367 per participant compared to a control group, delivering a 3.0x ROI. The study's methodology, assumptions, savings, feasibility, and credibility were independently reviewed by a global leader in risk management.

Key Points: 
  • The analysis demonstrated that Pelago reduced medical claims on an annual basis by $9,367 per participant compared to a control group, delivering a 3.0x ROI.
  • The study's methodology, assumptions, savings, feasibility, and credibility were independently reviewed by a global leader in risk management.
  • Medical claims of Pelago members with tobacco and alcohol use disorders were compared to a matched control group comprising nonparticipants in the Pelago programs with diagnoses of tobacco and alcohol use disorders in 2022.
  • "We've been able to confidently estimate and establish the impact of our substance use management program on overall healthcare costs and to identify the main drivers of overall cost savings."